^
    1d
    Discovery of pyrrolopyrimidinone inhibitors of the BCL6-SMRT corepressor interaction. (PubMed, Bioorg Med Chem)
    One series was advanced to a low micromolar confirmed hit via iterative rounds of compound optimization guided by structure activity relationships and co-crystal structures. Overall, we were able to use a rational, structure-based drug design approach to identify and advance a novel series of pyrrolopyrimidinone BCL6 BTB inhibitors.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • BCOR (BCL6 Corepressor)
    2d
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=150 --> 90
    Enrollment change
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • oxaliplatin • TQB2825
    2d
    Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Patrick C. Johnson, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    3d
    Multistep molecular trajectory of monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells. (PubMed, Biochem Biophys Res Commun)
    This indicates that the multistep molecular process of M-MDSC induction from PBMCs by the co-presence of HDBCLs begins with a transient early hyper-inflammatory phase and transitions into a post-inflammatory immunosuppressive phase. Our study demonstrates that treatments that target specific molecular phases regulated by cytokines could reduce M-MDSC induction and improve the effectiveness of immune cell therapy.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CD33 (CD33 Molecule) • IL10 (Interleukin 10) • MIF (Macrophage Migration Inhibitory Factor)
    3d
    Prospective, single-arm, multicenter clinical study of rituximab combined with cyclophosphamide, mitoxantrone liposomes, vincristine, and prednisone (R-CMOP) regimen in the treatment of previously untreated diffuse large B-cell lymphoma in patients aged 60 years or older or with underlying heart disease (ChiCTR2600117000)
    P=N/A, N=72, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • Marqibo (vincristine liposomal) • Duoenda (mitoxantrone liposomal) • vindesine
    3d
    A prospective, multicenter, single-arm clinical study to evaluate the efficacy and safety of glofitamab in combination with gemcitabine, dexamethasone, and cisplatin (Glofit-GDP) as salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (ChiCTR2600116920)
    P=N/A, N=43, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
    New trial
    |
    cisplatin • gemcitabine • dexamethasone • Columvi (glofitamab-gxbm)
    3d
    Application of tyrosine kinase-like orphan receptor 1 (ROR1) targeted imaging based on positron emission tomography (PET) in malignant tumors (ChiCTR2600116180)
    P=N/A, N=20, Recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    3d
    A prospective, multicenter, cocohort controlled clinical trial on the efficacy and safety of chidamide in maintenance treatment for newly diagnosed high-risk diffuse large B-cell lymphoma (ChiCTR2500112540)
    P=N/A, N=204, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epidaza (chidamide)
    3d
    Clinical Observation and Research on the Treatment of Newly Diagnosed Diffuse Large B-cell Lymphoma with TP53 Mutation/Deletion Using Selinexor Combined with Immunochemotherapy (ChiCTR2500112284)
    P=N/A, N=40, Not yet recruiting, Department of Hematology, Fifth Medical Center of the PLA General Hospital; Fifth Medical Center of the PLA General Hospital
    New trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Xpovio (selinexor)
    3d
    A retrospective analysis of ROR1 expression and previous antitumor efficacy and prognosis in patients with DLBCL (ChiCTR2600117598)
    P=N/A, N=25, Completed, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New trial
    3d
    A phase III clinical study of Purinostat Mesylate for Injection in patients with diffuse large B-cell lymphoma (ChiCTR2500114877)
    P3, N=390, Recruiting, West China Hospital of Sichuan University/Ruijin Hospital of Shanghai Jiao Tong University School of Medicine; Chengdu Zenitar Biomedical Technology C
    New P3 trial
    |
    Xpovio (selinexor) • purinostat
    3d
    Immuno and targeted therapy for Richter transformation to diffuse large B-cell lymphoma (ChiCTR2500109894)
    P2, N=34, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • PD-1 (Programmed cell death 1)
    |
    CD20 positive
    |
    lenalidomide • Tevimbra (tislelizumab-jsgr) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Columvi (glofitamab-gxbm)